journal
https://read.qxmd.com/read/38454132/late-onset-pulmonary-complications-following-allogeneic-hematopoietic-cell-transplantation-in-pediatric-patients-a-prospective-multicenter-study
#21
JOURNAL ARTICLE
Véronique Houdouin, Jean Christophe Dubus, Sophie Guilmin Crepon, Fanny Rialland, Bénedicte Bruno, Charlotte Jubert, Philippe Reix, Marlène Pasquet, Catherine Paillard, Dalila Adjaoud, Cyril Schweitzer, Muriel Le Bourgeois, Justine Pages, Adyla Yacoubi, Jean Hugues Dalle, Anne Bergeron, Christophe Delclaux
The primary objective of our multicenter prospective study was to describe the incidence of late-onset non-infectious pulmonary complications (LONIPCs) in children undergoing hematopoietic cell transplantation (HCT) using sensitive criteria for pulmonary function test (PFT) abnormalities including the non-specific pattern of airflow obstruction. Secondary objectives were to assess the factors associated with LONIPC occurrence and the sensitivity of the 2014 NIH-Consensus Criteria of bronchiolitis obliterans syndrome (BOS)...
March 7, 2024: Bone Marrow Transplantation
https://read.qxmd.com/read/38454131/long-term-follow-up-of-cancer-and-catastrophic-diseases-in-hematopoietic-stem-cell-donors-a-comprehensive-matched-cohort-study
#22
JOURNAL ARTICLE
Sung-Chao Chu, Chia-Jung Hsieh, Chi-Cheng Li, Shang-Hsien Yang, Szu-Chin Li, Woei-Yau Kao, Dian-Kun Li, Yi-Feng Wu, Ruey-Ho Kao, Kuo-Liang Yang, Tso-Fu Wang
Hematopoietic stem cell (HSC) transplantation, using either bone marrow (BM) or peripheral blood stem cells (PBSC), is a well-established therapy for various hematologic and non-hematologic diseases. However, the long-term health outcomes after HSC donation remain a major concern for several potential donors. Thus, we aimed to conduct a matched cohort study of 5003 unrelated donors (1099 BM and 3904 PBSC) and randomly selected 50,030 matched controls based on age, sex, and resident area from the donor registry between 1998 and 2018...
March 7, 2024: Bone Marrow Transplantation
https://read.qxmd.com/read/38443706/harmonizing-definitions-for-hematopoietic-recovery-graft-rejection-graft-failure-poor-graft-function-and-donor-chimerism-in-allogeneic-hematopoietic-cell-transplantation-a-report-on-behalf-of-the-ebmt-astct-cibmtr-and-apbmt
#23
JOURNAL ARTICLE
Anna Sureda, Paul A Carpenter, Andrea Bacigalupo, Vijaya Raj Bhatt, Josu de la Fuente, Aloysius Ho, Leslie Kean, Jong Wook Lee, Isabel Sánchez-Ortega, Bipin N Savani, Johannes Schetelig, Edward A Stadtmauer, Yoshiyuki Takahashi, Yoshiko Atsuta, John Koreth, Nicolaus Kröger, Per Ljungman, Shinichiro Okamoto, Uday Popat, Robert Soiffer, Heather E Stefanski, Mohamed A Kharfan-Dabaja
Despite emergence of novel therapies to treat hematologic malignancies, allogeneic hematopoietic cell transplantation (allo-HCT) remains an essential treatment modality capable of curing these diseases. Allo-HCT has been also shown to be curative in benign hematologic disorders such as aplastic anemia, sickle cell disease, and thalassemia, among others. Recently, the American Society for Transplantation and Cellular Therapy (ASTCT) published standardized definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism...
March 5, 2024: Bone Marrow Transplantation
https://read.qxmd.com/read/38443705/outcomes-and-prognosis-of-haploidentical-haematopoietic-stem-cell-transplantation-in-children-with-flt3-itd-mutated-acute-myeloid-leukaemia
#24
JOURNAL ARTICLE
Qianwen Shang, Lu Bai, Yifei Cheng, Pan Suo, Guanhua Hu, Chenhua Yan, Yu Wang, Xiaohui Zhang, Lanping Xu, Kaiyan Liu, Xiaojun Huang
The presence of internal tandem duplication mutations in the FMS-like tyrosine kinase 3 receptor (FLT3-ITD) is a poor prognostic predictor in paediatric patients with acute myeloid leukaemia (AML). We evaluated the treatment outcomes and prognostic factors of 45 paediatric patients with FLT3-ITD AML who achieved complete remission before haploidentical haematopoietic stem cell transplantation (haplo-HSCT) at our institution from 2012 to 2021. Among the 45 patients, the overall survival (OS), event‑free survival (EFS), and cumulative incidence of relapse (CIR) rates were 74...
March 5, 2024: Bone Marrow Transplantation
https://read.qxmd.com/read/38443704/role-of-upfront-autologous-transplant-for-peripheral-t-cell-lymphoma-patients-achieving-a-complete-remission-with-first-line-therapy-a-systematic-review-and-meta-analysis
#25
JOURNAL ARTICLE
L Girard, Y J Koh, L P Koh, Y L Chee, H L Chan, J Lee, S de Mel, L M Poon, M Samuel
There is currently no consensus on the role of upfront autologous transplantation (ASCT) for patients with peripheral T-cell lymphomas (PTCL), especially in patients achieving first complete remission (CR1) following chemotherapy, and data in the literature is conflicting. A systematic review and meta-analysis was performed to address this question. We searched key databases from January 2000 to February 2022. Six prospective and eleven retrospective studies were included among 2959 unique records. Median follow up in these studies ranged from 22 to 94 months...
March 5, 2024: Bone Marrow Transplantation
https://read.qxmd.com/read/38438648/reduced-toxicity-flubu3-versus-myeloablative-bucy-conditioning-in-acute-myeloid-leukemia-patients-who-received-first-allogeneic-hematopoietic-stem-cell-transplantation-in-measurable-residual-disease-negative-cr1
#26
JOURNAL ARTICLE
Silvia Park, Su-Yeon Bang, Daehun Kwag, Jong Hyuk Lee, Tong Yoon Kim, Joonyeop Lee, Gi June Min, Sung Soo Park, Seung-Ah Yahng, Young-Woo Jeon, Seung-Hwan Shin, Jae-Ho Yoon, Sung-Eun Lee, Byung Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Chang-Ki Min, Seok-Goo Cho, Jong Wook Lee, Hee-Je Kim
In the present study, reduced toxicity (FluBu3) and myeloablative (BuCy) conditioning were compared in patients with AML who received first allogeneic HSCT in MRD-negative CR1. The study included 124 adult patients who underwent HSCT from an HLA-matched (8/8) sibling, unrelated, or 1-locus mismatched (7/8) unrelated donor (MMUD). The median age was 45 years and intermediate cytogenetics comprised majority (71.8%). The 2-year OS, RFS, CIR and NRM for BuCy (n = 78, 62.9%) and FluBu3 (n = 46, 37...
March 4, 2024: Bone Marrow Transplantation
https://read.qxmd.com/read/38438647/hematopoietic-cell-transplantation-and-cellular-therapies-in-europe-2022-car-t-activity-continues-to-grow-transplant-activity-has-slowed-a-report-from-the-ebmt
#27
JOURNAL ARTICLE
Jakob R Passweg, Helen Baldomero, Fabio Ciceri, Rafael de la Cámara, Bertram Glass, Raffaella Greco, Mette D Hazenberg, Krzysztof Kalwak, Donal P McLornan, Bénédicte Neven, Zinaida Perić, Antonio M Risitano, Annalisa Ruggeri, John A Snowden, Anna Sureda
In 2022, 46,143 HCT (19,011 (41.2%) allogeneic and 27,132 (58.8%) autologous) in 41,854 patients were reported by 689 European centers. 4329 patients received advanced cellular therapies, 3205 of which were CAR-T. An additional 2854 patients received DLI. Changes compared to the previous year were an increase in CAR-T treatments (+27%) and decrease in allogeneic (-4.0%) and autologous HCT (-1.7%). Main indications for allogeneic HCT were myeloid malignancies (10,433; 58.4%), lymphoid malignancies (4,674; 26...
March 4, 2024: Bone Marrow Transplantation
https://read.qxmd.com/read/38431763/clostridium-butyricum-miyairi-588-contributes-to-the-maintenance-of-intestinal-microbiota-diversity-early-after-haematopoietic-cell-transplantation
#28
JOURNAL ARTICLE
Kentaro Fukushima, Hayami Kudo, Kentaro Oka, Atsushi Hayashi, Makoto Onizuka, Shinsuke Kusakabe, Akihisa Hino, Motomichi Takahashi, Kiyoshi Takeda, Masaki Mori, Kiyoshi Ando, Naoki Hosen
In patients undergoing haematopoietic stem-cell transplantation (HSCT), the intestinal microbiota plays an important role in prognosis, transplant outcome, and complications such as graft-versus-host disease (GVHD). Our prior research revealed that patients undergoing HSCT substantially differed from healthy controls. In this retrospective study, we showed that administering Clostridium butyricum MIYAIRI 588 (CBM588) as a live biotherapeutic agent is associated with maintaining intestinal microbiota in the early post-HSCT period...
March 2, 2024: Bone Marrow Transplantation
https://read.qxmd.com/read/38424174/prevalence-of-osteoporosis-among-patients-after-stem-cell-transplantation-a-systematic-review-and-meta-analysis
#29
JOURNAL ARTICLE
Yu-Mei Yang, Shu-Jin Guo, Rong Xiao, Xi-Jie Yu, Yu-Ping Liu, Ping Shuai
The prevalence of osteoporosis in post stem cell transplantation (SCT) is poorly defined. We performed a systematic review and meta-analysis to determine the prevalence of osteoporosis in patients with hematologic diseases who underwent SCT. PubMed, EMBASE, and Web of Science were searched (from inception to 30th April 2023) using Medical Subject Headlines to find studies that assessed the prevalence of osteoporosis among post SCT. Thirteen articles meeting the inclusion criteria were included in the analysis...
February 29, 2024: Bone Marrow Transplantation
https://read.qxmd.com/read/38418622/how-to-decrease-bone-marrow-collection-volume-and-risk-contaminations-via-the-operating-room-cell-concentration
#30
LETTER
Yoann Grimaud, Flore Sicre de Fontbrune, David Michonneau, Aude Desnoyer, Régis Peffault de Latour, Jérôme Larghero, Justine Nasone, Lionel Faivre
No abstract text is available yet for this article.
February 28, 2024: Bone Marrow Transplantation
https://read.qxmd.com/read/38413823/international-recommendations-for-screening-and-preventative-practices-for-long-term-survivors-of-transplantation-and-cellular-therapy-a-2023-update
#31
REVIEW
Seth J Rotz, Neel S Bhatt, Betty K Hamilton, Christine Duncan, Mahmoud Aljurf, Yoshiko Atsuta, Kristen Beebe, David Buchbinder, Peggy Burkhard, Paul A Carpenter, Naeem Chaudhri, Mohamed Elemary, Mahmoud Elsawy, Gregory M T Guilcher, Nada Hamad, Amado Karduss, Zinaida Peric, Duncan Purtill, Douglas Rizzo, Morgani Rodrigues, Maria Belén Rosales Ostriz, Nina Salooja, Helene Schoemans, Adriana Seber, Akshay Sharma, Alok Srivastava, Susan K Stewart, K Scott Baker, Navneet S Majhail, Rachel Phelan
As hematopoietic cell transplantation (HCT) and cellular therapy expand to new indications and international access improves, the volume of HCT performed annually continues to rise. Parallel improvements in HCT techniques and supportive care entails more patients surviving long-term, creating further emphasis on survivorship needs. Survivors are at risk for developing late complications secondary to pre-, peri- and post-transplant exposures and other underlying risk-factors. Guidelines for screening and preventive practices for HCT survivors were originally published in 2006 and updated in 2012...
February 27, 2024: Bone Marrow Transplantation
https://read.qxmd.com/read/38413822/early-lymphocyte-reconstitution-and-viral-infections-in-adolescents-and-adults-transplanted-for-sickle-cell-disease
#32
LETTER
Loïc Vasseur, Alexis Cuffel, Corinne Pondarré, Jean-Hugues Dalle, Florian Chevillon, Aude-Marie Fourmont, Edouard Flamarion, Karima Yakouben, Valérie Guérin-El Khourouj, Florence Morin, Clara Ibanez, Régis Peffault de Latour, Nicolas Boissel, Jean-Benoit Arlet, Hélène Moins-Teisserenc, Sophie Caillat-Zucman, Nathalie Dhédin
No abstract text is available yet for this article.
February 27, 2024: Bone Marrow Transplantation
https://read.qxmd.com/read/38409332/mesenchymal-stromal-cell-therapy-for-covid-19-acute-respiratory-distress-syndrome-a-double-blind-randomised-controlled-trial
#33
JOURNAL ARTICLE
María E Martínez-Muñoz, Concepción Payares-Herrera, Inés Lipperheide, Rosa Malo de Molina, Isabel Salcedo, Rosalía Alonso, Trinidad Martín-Donaire, Rocío Sánchez, Rocío Zafra, Miguel García-Berciano, Andrea Trisán-Alonso, Manuel Pérez-Torres, Antonio Ramos-Martínez, Piedad Ussetti, Juan J Rubio, Cristina Avendaño-Solà, Rafael F Duarte
Mesenchymal stromal cells (MSC) have immunomodulatory and tissue-regenerative properties and have shown promising results in acute respiratory distress syndrome (ARDS) of multiple causes, including COVID-19. We conducted a randomised (1:1), placebo-controlled, double-blind clinical trial to assess the efficacy and safety of one bone marrow-derived MSC infusion in twenty patients with moderate to severe ARDS caused by COVID-19. The primary endpoint (increase in PaO2/FiO2 ratio from baseline to day 7, MSC 83...
February 26, 2024: Bone Marrow Transplantation
https://read.qxmd.com/read/38402346/ruxolitinib-for-the-treatment-of-acute-and-chronic-graft-versus-host-disease-in-children-a-systematic-review-and-individual-patient-data-meta-analysis
#34
JOURNAL ARTICLE
Francesco Baccelli, Francesca Gottardi, Edoardo Muratore, Davide Leardini, Antonio Giacomo Grasso, Davide Gori, Tamara Belotti, Arcangelo Prete, Riccardo Masetti
Steroid-refractory graft-versus-host disease (SR-GvHD) represents a major complication of pediatric allogenic hematopoietic stem cell transplantation. Ruxolitinib, a selective JAK 1-2 inhibitor, showed promising results in the treatment of SR-GvHD in adult trial, including patients >12 years old. This systematic review aims to evaluate ruxolitinib use for SR-GvHD in the pediatric population. Among the 12 studies included, ruxolitinib administration presented slight differences. Overall response rate (ORR) ranged from 45% to 100% in both acute and chronic GvHD...
February 24, 2024: Bone Marrow Transplantation
https://read.qxmd.com/read/38402345/rituximab-added-to-conditioning-regimen-significantly-improves-erythroid-engraftment-in-major-incompatible-abo-group-hematopoietic-stem-cell-transplantation
#35
JOURNAL ARTICLE
Maria Chiara Finazzi, Alessandra Weber, Chiara Pavoni, Anna Grassi, Maria Caterina Micò, Alessandra Algarotti, Federico Lussana, Alessandro Rambaldi
ABO-group major incompatibility hematopoietic stem cell transplantation (HSCT) increases the risk of delayed red cell engraftment and other immunological complications. In this study, we evaluated the efficacy of pre-transplant infusion of rituximab in patients with ABO-incompatibility in improving red blood cell engraftment after HSCT, measured by time to reach transfusion independence. We performed a retrospective, single-center study including 131 consecutive patients transplanted with major or bidirectional ABO-incompatible grafts between 1st January 2013 and 31st December 2019...
February 24, 2024: Bone Marrow Transplantation
https://read.qxmd.com/read/38402344/real-world-experience-with-ruxolitinib-therapy-for-steroid-refractory-acute-graft-versus-host-disease
#36
JOURNAL ARTICLE
Alistair Murray, Swe Mar Linn, Benoit Yu, Igor Novitzky-Basso, Jonas Mattsson, Michael Kennah, Mohamed Elemary, Jennifer White, Christopher Lemieux, Kareem Jamani, Dennis Dong Hwan Kim
Acute graft versus host disease (aGVHD) is a complication of allogeneic hematopoietic stem cell transplant (HCT) and is associated with significant morbidity and mortality. Steroid refractory aGVHD (SR-aGVHD) carries a particularly grim prognosis. Ruxolitinib has shown promise for treatment of SR-aGVHD in a phase 3 trial; however, safety and efficacy data outside of the clinical trial setting is lacking. We performed a multicenter retrospective study to examine the response to ruxolitinib and its efficacy in patients with SR-aGVHD...
February 24, 2024: Bone Marrow Transplantation
https://read.qxmd.com/read/38396211/remuneration-of-donors-for-cell-and-gene-therapies-an-update-on-the-principles-and-perspective-of-the-world-marrow-donor-association
#37
REVIEW
Lina Hamad, Salmah Mahmood Ahmed, Eefke van Eerden, Suzanna M van Walraven, Laura Machin
The cell and gene therapy (CGT) sector has witnessed significant advancement over the past decade, the inception of advanced therapy medicinal products (ATMPs) being one of the most transformational. ATMPs treat serious medical conditions, in some cases providing curative therapy for seriously ill patients. There is interest in pivoting the ATMP development from autologous based treatments to allogenic, to offer faster and greater patient access that should ultimately reduce treatment costs. Consequently, starting material from allogenic donors is required, igniting ethical issues associated with financial gains and donor remuneration within CGT...
February 23, 2024: Bone Marrow Transplantation
https://read.qxmd.com/read/38383715/prognostic-factors-in-448-newly-diagnosed-multiple-myeloma-receiving-bortezomib-based-induction-impact-of-asct-transplant-refusal-and-high-risk-mm
#38
JOURNAL ARTICLE
Hoi Ki Karen Tang, Chi Yeung Fung, Yu Yan Hwang, Harold Lee, Grace Lau, Sze Fai Yip, Bonnie Kho, Chi Kuen Lau, Kwan Hung Leung, Elaine Au, Eric Tse, Joycelyn Sim, Yok Lam Kwong, Chor Sang Chim
In Hong Kong, newly diagnosed multiple myeloma (NDMM) receives bortezomib-based triplet induction. Upfront autologous stem cell transplant (ASCT) is offered to transplant eligible (TE) patients (NDMM ≤ 65 years of age), unless medically unfit (TE-unfit) or refused (TE-refused). Data was retrieved for 448 patients to assess outcomes. For the entire cohort, multivariate analysis showed that male gender (p = 0.006), international staging system (ISS) 3 (p = 0.003), high lactate dehydrogenase (LDH) (p = 7...
February 21, 2024: Bone Marrow Transplantation
https://read.qxmd.com/read/38383714/overlap-chronic-gvhd-is-associated-with-adverse-survival-outcomes-compared-to-classic-chronic-gvhd
#39
JOURNAL ARTICLE
Lev Gorfinkel, Sharmila Raghunandan, Benjamin Watkins, Kyle Hebert, Donna S Neuberg, Brandi Bratrude, Kayla Betz, Alison Yu, Sung W Choi, Jeffrey Davis, Christine Duncan, Roger Giller, Michael Grimley, Andrew C Harris, David Jacobsohn, Nahal Lalefar, Nosha Farhadfar, Michael A Pulsipher, Shalini Shenoy, Aleksandra Petrovic, Kirk R Schultz, Gregory A Yanik, Bruce R Blazar, John T Horan, Amelia Langston, Leslie S Kean, Muna Qayed
Chronic graft-versus-host-disease (cGVHD) is divided into two subtypes: classic (absence of acute GVHD features) and overlap cGVHD ('ocGVHD'), in which both chronic and acute GVHD clinical features are present simultaneously. While worse outcomes with ocGVHD have been reported, there are few recent analyses. We performed a secondary analysis of data from the ABA2 trial (N = 185), in which detailed GVHD data were collected prospectively and systematically adjudicated. Analyses included cumulative incidence of classic versus ocGVHD, their specific organ manifestations, global disease severity scores, non-relapse mortality (NRM), disease-free survival (DFS) and overall survival (OS) in these two cGVHD subtypes...
February 21, 2024: Bone Marrow Transplantation
https://read.qxmd.com/read/38383713/fludarabine-treosulfan-versus-fludarabine-melphalan-or-busulfan-cyclophosphamide-conditioning-in-older-aml-or-mds-patients-a-clinical-trial-to-registry-data-comparison
#40
JOURNAL ARTICLE
Dietrich Wilhelm Beelen, Simona Iacobelli, Linda Koster, Dirk-Jan Eikema, Anja van Biezen, Friedrich Stölzel, Fabio Ciceri, Wolfgang Bethge, Peter Dreger, Eva-Maria Wagner-Drouet, Péter Reményi, Matthias Stelljes, Miroslaw Markiewicz, Donal P McLornan, Ibrahim Yakoub-Agha, Mohamad Mohty
A randomized study (acronym: MC-FludT.14/L Trial II) demonstrated that fludarabine plus treosulfan (30 g/m²) was an effective and well tolerated conditioning regimen for allogeneic hematopoietic cell transplantation (allo-HCT) in older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). To further evaluate this regimen, all 252 study patients aged 50 to 70 years were compared with similar patients, who underwent allo-HCT after fludarabine/melphalan (140 mg/m²) (FluMel) or busulfan (12...
February 21, 2024: Bone Marrow Transplantation
journal
journal
20054
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.